Wells Fargo & Company MN Buys 33,214 Shares of Insmed Incorporated (NASDAQ:INSM)

Wells Fargo & Company MN grew its position in Insmed Incorporated (NASDAQ:INSM) by 26.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 160,709 shares of the biopharmaceutical company’s stock after purchasing an additional 33,214 shares during the period. Wells Fargo & Company MN owned about 0.09% of Insmed worth $11,095,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC raised its stake in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC boosted its stake in Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares during the period. Spire Wealth Management bought a new position in Insmed during the 4th quarter worth about $47,000. Smartleaf Asset Management LLC boosted its position in Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in Insmed during the 4th quarter worth about $86,000.

Insider Transactions at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at approximately $25,742,347.58. This represents a 5.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the sale, the insider now directly owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. This represents a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 464,967 shares of company stock valued at $37,142,046 over the last ninety days. 3.00% of the stock is owned by company insiders.

Insmed Stock Up 0.1 %

Shares of NASDAQ INSM opened at $71.07 on Wednesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The firm has a market cap of $12.92 billion, a PE ratio of -12.71 and a beta of 1.07. The company has a 50 day simple moving average of $75.79 and a 200 day simple moving average of $73.62.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, research analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on INSM. Bank of America increased their price target on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. UBS Group lifted their price objective on shares of Insmed from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Guggenheim reissued a “buy” rating and issued a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Stifel Nicolaus cut their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Finally, Morgan Stanley upped their price target on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.